Reaction to the Global Fund's decisions on Round 11 and grant renewals
1 February 2012. Related: Treatment access.
Treatment access
Activists oppose Gates Foundation funding study using low dose d4T
1 February 2012. Related: Treatment access.
Global Fund cancels Round 11 and introduces new rules for grant renewals
1 December 2011. Related: Treatment access.
FDA approval of generic ARVs
1 December 2011. Related: Treatment access.
We need the Patent Pool to work
1 December 2011. Related: Treatment access.
FDA approval of generic ARVs
1 October 2011. Related: Treatment access.
Global Fund adopts restructuring recommendations and close to 50% funding shortfall for next round of grants
1 October 2011. Related: Treatment access.
Monitoring treatment in resource limited settings: results from PHPT-3 and Stratall ANRS12110/ESTER trials
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
DART: high rates of viral suppression after five years and a single CD4 test with a threshold of 250 cells/mm3 could reduce unnecessary switching
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
Lopinavir/r monotherapy used as second-line therapy in resource-limited settings
1 August 2011. Related: Conference reports, Treatment strategies, Treatment access.
Gilead signs up for Medicines Patent Pool
1 August 2011. Related: Treatment access.
FDA approval of generic ARVs
1 August 2011. Related: Treatment access.
Patents and the pipeline: is access under threat?
14 July 2011. Related: Pipeline report, Treatment access.
An audit of HIV care provision for Immigration Removal Centre patients
1 May 2011. Related: Conference reports, Treatment access.
FDA approval of generic ARVs
1 April 2011. Related: Treatment access.
Global Fund reports rise in people on treatment
1 April 2011. Related: Treatment access.
UK increases funding to the Global Fund
1 April 2011. Related: Treatment access.
UK government development priorities and HIV
1 April 2011. Related: Treatment access.
Update on the Patent Pool
1 April 2011. Related: Treatment access.
TRIPS agreement flexibilities provide opportunities for improved access to ARVs
1 April 2011. Related: Treatment access.
Driving a decade of change: HIV/AIDS, patents and access to medicines for all
1 April 2011. Related: Treatment access.
FDA approval of generic ARVs
1 February 2011. Related: Treatment access.
ART distribution and adherence support by community groups in Mozambique
1 February 2011. Related: Treatment access.
Commentary: corruption by Global Fund grant implementers
1 February 2011. Related: Treatment access.
Virological findings from the SARA trial ofboosted protease inhibitor monotherapy
1 December 2010. Related: Conference reports, Antiretrovirals, Treatment access, Virology.
Shortfall in funding for the Global Fund
1 December 2010. Related: Treatment access.
FDA approval of generic ARVs
1 December 2010. Related: Treatment access.
Europe! HANDS OFF OUR MEDICINE
1 December 2010. Related: Treatment access.
DNP+ president uses 5ml of blood to meet Carla Bruni-Sarkozy
1 December 2010. Related: Treatment access.
Medicines Patent Pool: first research funder announced
1 December 2010. Related: Treatment access.
FDA approval of generic ARVs
1 October 2010. Related: Treatment access.
IAS highlight funding shortfall crisis for Global Fund
1 October 2010. Related: Treatment access.
The need for expanded access to experimental medicines for drug-resistant TB
1 October 2010. Related: Treatment access.
Indian activists challenge proposed EU tradeagreements: Global access to Indian generic ARVs threatened
1 October 2010. Related: Treatment access.
Russian HIV activists arrested in Red Square for protesting drug stock-outs
1 October 2010. Related: Treatment access.
Chinese HIV positive activist Tian Xi to go on trial on trumped up charges
1 October 2010. Related: Treatment access.
US waiting lists increase by over 300% in five months
1 October 2010. Related: Treatment access.
Raltegravir approved inScotland
26 August 2010. Related: Antiretrovirals, Treatment access.
Atazanavir/r approved in Europefor children aged 6 to 18 years
26 August 2010. Related: Antiretrovirals, Treatment access, Paediatric care.
FDA finally approves 4th generation HIV Ag/Ab test in the US
26 August 2010. Related: Antiretrovirals, Treatment access, Pregnancy, Paediatric care, Diagnostics.
FDA approval of generic ARVs
26 August 2010. Related: Treatment access.
FDA approval of generic ARVs
1 June 2010. Related: Treatment access.
U.S. government leading backlash against AIDS funding
1 June 2010. Related: Treatment access.
Evidence from six countries confirms fears of People Living With HIV/AIDS: treatment rationing is escalating
1 June 2010. Related: Treatment access, Treatment advocacy.
Launch of the 10th funding round and other outcomes from the Global Fund
1 June 2010. Related: Treatment access.
FDA approval of generic ARVs
2 April 2010. Related: Treatment access.
Waiting lists grow in the US
2 April 2010. Related: Treatment access.
South African antiretroviral treatment guidelines (2010)
2 April 2010. Related: Treatment access, Guidelines.
Tenofovir registered in Russia
2 April 2010. Related: Treatment access.
MSF criticise Abbott over new ritonavir formulation
2 April 2010. Related: Treatment access.
FDA approval of generic ARVs
6 February 2010. Related: Treatment access.
UNITAID decision to fund ‘patent pool’ to boost access to new medicines
6 February 2010. Related: Treatment access.
PEPFAR launches five-year strategy
6 February 2010. Related: Treatment access.
Global Fund approves US$2.4 billion in new grants
6 February 2010. Related: Treatment access.
AIDS and mortality in South Africa
30 December 2009. Related: Treatment access.
Punishing success in tackling AIDS: funders retreat could wipe out health gains in HIV affected countries
30 December 2009. Related: Treatment access.
FDA approval of generic ARVs
30 December 2009. Related: Treatment access.
Five-year survival rates of 87% without routine CD4 or laboratory monitoring in DART study demonstrate an important model for ARV access programmes
23 August 2009. Related: Conference reports, Treatment access.
Access to HIV treatment for UK prisoners
3 June 2009. Related: Treatment access, BHIVA news.
Lost benefit of ARVs in South Africa
10 February 2009. Related: Treatment access.
FDA approval of generic ARVs
26 December 2008. Related: Treatment access.
Brazil rejects Gilead patent on tenofovir
30 October 2008. Related: Treatment access.
PEPFAR bill may lift US HIV travel and residency ban
30 October 2008. Related: Treatment access.
Atripla to be licensed in Latin America and the Asia-Pacific region
30 October 2008. Related: Treatment access.
FDA approval of generic ARVs
24 October 2008. Related: Treatment access.